<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977480</url>
  </required_header>
  <id_info>
    <org_study_id>HM007UC2S01</org_study_id>
    <nct_id>NCT03977480</nct_id>
  </id_info>
  <brief_title>Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Different Dosing Regimens of Hemay007 in Patients With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Hemay Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Hemay Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study adopts a multicenter, randomized, double-blind, low-medium-high dose group and&#xD;
      placebo parallel controlled clinical study design. After screening, patients with active&#xD;
      ulcerative colitis who meet the inclusion criteria and do not meet the exclusion criteria&#xD;
      will be randomized by 1:1:1:1 to Hemay007 400 mg BID group, 800 mg QD group, 600 mg BID group&#xD;
      or placebo group, with proposed 72 cases in each group. After 12 weeks of double-blind&#xD;
      inductive treatment period, the patients will enter the Hemay007 open treatment period of 12&#xD;
      weeks when Hemay007 600 mg BID will be used as the medication regimen. All randomized&#xD;
      subjects who have received the investigational drug should be subjected to a 4-week&#xD;
      observation after the end of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      his study adopts a multicenter, randomized, double-blind, low-medium-high dose group and&#xD;
      placebo parallel controlled clinical study design. After screening, patients with active&#xD;
      ulcerative colitis who meet the inclusion criteria and do not meet the exclusion criteria&#xD;
      will be randomized by 1:1:1:1 to Hemay007 400 mg BID group, 800 mg QD group, 600 mg BID group&#xD;
      or placebo group, with proposed 72 cases in each group. After 12 weeks of double-blind&#xD;
      inductive treatment period, the patients will enter the Hemay007 open treatment period of 12&#xD;
      weeks when Hemay007 600 mg BID will be used as the medication regimen. All randomized&#xD;
      subjects who have received the investigational drug should be subjected to a 4-week&#xD;
      observation after the end of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical response</measure>
    <time_frame>12-week</time_frame>
    <description>12-week clinical response rate Definition of clinical response: defined as full Mayo score decreased by ≥ 3 points compared with baseline and lowered by ≥ 30% compared with baseline, combined with the rectal bleeding subscore decreased by ≥ 1 point compared with baseline, or the absolute value of rectal bleeding subscore ≤ 1 point.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Hemay007 400 mg BID group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will orally take Hemay007 tablets 400 mg BID for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemay007 800 mg QD group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will orally take Hemay007 tablets 800 mg QD for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemay007 600 mg BID group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will orally take Hemay007 tablets 600 mg BID for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will orally take placebo tablets for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemay007</intervention_name>
    <description>Hemay007 will be orally administered.</description>
    <arm_group_label>Hemay007 400 mg BID group</arm_group_label>
    <arm_group_label>Hemay007 600 mg BID group</arm_group_label>
    <arm_group_label>Hemay007 800 mg QD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the trial and signing the informed consent forms;&#xD;
&#xD;
          -  Age ≥18 years old and ≤70 years old, male or female;&#xD;
&#xD;
          -  Diagnosed as ulcerative colitis (UC) ≥ 3 months at screening with clinical&#xD;
             manifestations and evidence of endoscopy and confirmed by histopathological reports;&#xD;
&#xD;
          -  Active ulcerative colitis with full Mayo score ≥ 4 points, and the subscore&#xD;
             &quot;endoscopic findings&quot; in the Mayo endoscopic score within 14 days before randomization&#xD;
             ≥ 2 points;&#xD;
&#xD;
          -  UC treatment failure or intolerance (intolerance is defined as the discontinuation of&#xD;
             drug use due to adverse reactions judged by the investigators) experienced by patients&#xD;
             using at least one of the following:&#xD;
&#xD;
        Oral administration of sulfasalazine (SASP) and/or 5-aminosalicylic acid (5-ASA); Oral&#xD;
        administration of corticosteroids; Azathioprine or 6-mercaptopurine; Anti-TNF-α treatment:&#xD;
        infliximab or adalimumab, etc.;&#xD;
&#xD;
          -  If the patient is using the following drugs to treat ulcerative colitis at the time of&#xD;
             screening, it is necessary to receive stable treatment during the screening period and&#xD;
             the following requirements during the study period are as follows:&#xD;
&#xD;
          -  Oral administration of sulfasalazine (SASP) and/or 5-aminosalicylic acid (5-ASA)&#xD;
             maintaining stable for at least ≥ 2 weeks prior to endoscopy during the screening&#xD;
             period and maintaining stable during the study period; and/or&#xD;
&#xD;
          -  Oral administration of low-dose corticosteroids (≤25 mg/d prednisolone or equivalent&#xD;
             drug dose) maintaining stable for at least ≥ 2 weeks prior to endoscopy during the&#xD;
             screening period;&#xD;
&#xD;
          -  At least one of the following effective contraceptive methods should be adopted for&#xD;
             female patients with fertility and male patients who have not undergone vasectomy&#xD;
             during the entire study period from the date of signing the informed consent to 3&#xD;
             months after the last dose. Acceptable contraceptive methods in this study include: a.&#xD;
             abstinence; b. hormones (oral intake, patch, ring, injection, implantation) combined&#xD;
             with male condoms. This measure must be applied at least 30 days prior to the first&#xD;
             administration of investigational drug, otherwise another acceptable method of&#xD;
             contraception must be used; c. intra-uterine device (IUD) combined with male condoms;&#xD;
             d. barrier method (diaphragm, cervical cap, sponge) combined with male condoms;&#xD;
             exceptional circumstances: a) females who have been menopausal for 5 years and more,&#xD;
             and b) surgical sterilization (proof should be provided).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women, or women planning to become pregnant during the study;&#xD;
&#xD;
          -  Knownto be allergic to any component of Hemay007 tablets (the main component is&#xD;
             hemay007, and the main excipients are microcrystalline cellulose, pregelatinized&#xD;
             starch, croscarmellose sodium, magnesium stearate);&#xD;
&#xD;
          -  Patients with suspected or confirmed Crohn's disease, undiagnosed types of colitis,&#xD;
             fulminant colitis, toxic megacolon, microscopic colitis, ischemic colitis or&#xD;
             radioactive colitis based on medical history and endoscopy and/or histological&#xD;
             results;&#xD;
&#xD;
          -  Patients with the disease confined to the rectum (ulcerative proctitis) according to&#xD;
             the endoscopy during screening;&#xD;
&#xD;
          -  Patients who have undergone surgical treatment for ulcerative colitis or who require&#xD;
             surgery during the study;&#xD;
&#xD;
          -  Patientswith evidence of pathogenic intestinal infection;&#xD;
&#xD;
          -  Patients receiving the following treatments:&#xD;
&#xD;
        Patients who have used azathioprine/6-mercaptopurine, methotrexate within 7 days before&#xD;
        randomization; Patients who have used cyclosporine, mycophenolate mofetil,&#xD;
        tacrolimus/sirolimus within 4 weeks before randomization; Patients who have used interferon&#xD;
        within 8 weeks before randomization; Patients who have received anti-TNF-α treatment within&#xD;
        8 weeks before randomization; Intravenous corticosteroids or rectal administration of&#xD;
        corticosteroids or rectal administration of 5-ASA within 2 weeks prior to randomization;&#xD;
        Patients who have used thalidomide within 8 weeks before randomization;Patients who have&#xD;
        received antibiotic treatment within 1 week before randomization;&#xD;
&#xD;
        • Patients with positive mycobacterium tuberculosis or potential mycobacterium tuberculosis&#xD;
        infection, i.e. patients conforming to any one of the following definitions will be&#xD;
        excluded: QuantiFERON®-TB Gold (QFT-G) or T-SPOT.TB test positive or purified protein&#xD;
        derivative (PPD) skin test induration result ≥ 5 mm (within 3 months before screening);&#xD;
        Chest imaging examination indicating positive tuberculosis (TB) infection lesion within 3&#xD;
        months prior to screening; History of latent or active TB infection;&#xD;
&#xD;
          -  Patients with hemoglobin &lt;8 g/dL or hematocrit &lt;30%, white blood cells &lt;3.0 × 10^9/L&#xD;
             or neutrophils &lt;1.2 × 10^9/L, platelets &lt;100 × 10^09/L at screening;&#xD;
&#xD;
          -  Total bilirubin (TBIL), aspartate aminotransferase (AST) or alanine aminotransferase&#xD;
             (ALT) ≥ 2 upper limits of normal (ULN) at screening;&#xD;
&#xD;
          -  Glomerular filtration rate (eGFR) ≤ 40 ml/min;&#xD;
&#xD;
          -  Patients with hereditary immunodeficiency disease;&#xD;
&#xD;
          -  Patients with a history of lymphoproliferative disorders (e.g. EBV-related&#xD;
             lymphoproliferative disorders), or with lymphoma, leukemia, myeloproliferative&#xD;
             disease, multiple myeloma;&#xD;
&#xD;
          -  Patients previously receiving drugs or treatment depleting lymphocytes (e.g.&#xD;
             alemtuzumab, alkylating agents (e.g. cyclophosphamide or chlorambucil), total lymph&#xD;
             node radiotherapy, etc.), however, patients can be enrolled if they used rituximab or&#xD;
             other selective B lymphocyte depleting drugs more than one year before screening;&#xD;
&#xD;
          -  Lymphocyte apheresis or selective mononuclear granulocyte apheresis was performed&#xD;
             within 12 months before the screening or is planned to be performed during the study;&#xD;
&#xD;
          -  The electrocardiogram during the screening period is abnormal and clinically&#xD;
             significant, with the safety risk possibly increasing judged by the investigator;&#xD;
&#xD;
          -  Blood donation ≥500 ml within 2 months before randomization;&#xD;
&#xD;
          -  Patients with malignant tumor or with a history of malignancy other than well-treated&#xD;
             or resected basal cell or squamous cell skin cancer;&#xD;
&#xD;
          -  Patients with conditions that may affect oral drug absorption, e.g. gastrectomy or&#xD;
             clinically significant diabetes-related gastrointestinal disorders, or specific types&#xD;
             of obesity surgery such as gastric bypass, however, patients only subjected to the&#xD;
             division of the stomach into independent chambers, like gastric banding, will not be&#xD;
             excluded;&#xD;
&#xD;
          -  Patients with previous surgery on small intestine or colon and with evidence of&#xD;
             colonic dysplasia or intestinal stenosis; [21] Patients with chronic hepatitis B virus&#xD;
             (HBV) infection (hepatitis B surface antigen (HBsAg), hepatitis B surface antibody&#xD;
             (HBsAb) and hepatitis B core antibody (HBcAb) should be assessed for all patients&#xD;
             during screening: patients with positive hepatitis B surface antigen (HBsAg) will be&#xD;
             excluded; patients with HBsAg (negative), HBsAb (negative or positive) and HBcAb&#xD;
             (positive) should be tested for HBV-DNA, and if the HBV-DNA result is positive,&#xD;
             patient will be excluded; if the HBV-DNA result is negative, patients can be enrolled&#xD;
             in the study.), chronic hepatitis C virus (HCV) infection (patients with positive&#xD;
             hepatitis C virus antibody (HCVAb) excluded) or human immunodeficiency virus (HIV)&#xD;
             infection (patients with positive human immunodeficiency virus (HIV) antibody&#xD;
             excluded);&#xD;
&#xD;
          -  Varicella, herpes zoster or other serious viral infections within 6 weeks prior to&#xD;
             screening;&#xD;
&#xD;
          -  Patients receive any live vaccine at present or has received any live vaccine within 8&#xD;
             weeks prior to randomization;&#xD;
&#xD;
          -  Major organ transplantation (e.g. heart, lung, kidney, liver) or hematopoietic stem&#xD;
             cell/bone marrow transplantation;&#xD;
&#xD;
          -  Application of other drugs or devices of research nature within 3 months prior to&#xD;
             randomization;&#xD;
&#xD;
          -  Patients with primary sclerosing cholangitis;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Other conditions that the investigator judges as unsuitable to participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaowei Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>XiangYa Hospital CentralSouth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yueying Zhen, Ph.D.</last_name>
    <phone>86-22-2492-9366</phone>
    <email>zhenyueying@hemay.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naizhong Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University International Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiangchun Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yulan Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Army Special Medical Center</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jun Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Army Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lei Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jianwei Zheng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiaoping Lv, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bingrong Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhengzhou People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yingjie Ma, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji hospital, tongji medical college, huazhong university of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dean Tian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XiangYa Hospital CentralSouth University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiaowei Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulou Hospital Affiliated to Nanjing University School of Medicine</name>
      <address>
        <city>Nankín</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiaoping Zou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xu Shu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital Affiliated to China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Changqing Zheng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mingjun Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bingzhong Su, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Autonomous Region People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jianjun Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Qinghai University</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xuehong Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hongwei Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jinshui Zhu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xizhong Shen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Junping Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bangmao Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ping Yao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chunxiao Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

